Terms: = Colorectal cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Clinical Outcome
3 results:
1. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Thomaidis T; Maderer A; Formentini A; Bauer S; Trautmann M; Schwarz M; Neumann W; Kittner JM; Schad A; Link KH; Rey JW; Weinmann A; Hoffman A; Galle PR; Kornmann M; Moehler M
J Exp Clin Cancer Res; 2014 Oct; 33(1):83. PubMed ID: 25272957
[TBL] [Abstract] [Full Text] [Related]
2. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
Pommier AJ; Shaw R; Spencer SK; Morgan SR; Hoff PM; Robertson JD; Barry ST; Jürgensmeier JM
Br J Cancer; 2014 Oct; 111(8):1590-604. PubMed ID: 25121956
[TBL] [Abstract] [Full Text] [Related]
3. Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?
Tsirlis TD; Papastratis G; Masselou K; Tsigris C; Papachristodoulou A; Kostakis A; Nikiteas NI
World J Gastroenterol; 2008 May; 14(17):2691-701. PubMed ID: 18461654
[TBL] [Abstract] [Full Text] [Related]
